Literature DB >> 19802965

The in-vitro properties of ceftazidime.

P B Harper1.   

Abstract

Ceftazidime showed a high level of in-vitro antibacterial activity against the Enterobacteriaceae with geometric mean MICs of 0.07-0.5 mg/l and at least 90% of isolates sensitive to 8 mg/l. This cephalosporin was at least as active as gentamicin against gentamicin-sensitive Enterobacteriaceae and showed no significant reduction in activity against gentamicin-resistant strains. The activity of ceftazidime against Pseudomonas species was of special note with all the 204 isolates tested sensitive to 8 mg/l and was highly active against gentamicin-resistant strains. Activity against Staphylococcus aureus was moderate, whilst streptococci were highly susceptible. Activity against Bacteroides fragilis was moderate but a range of anaerobic bacilli and cocci were sensitive. Ceftazidime showed no significant inoculum effects, was rapidly bactericidal and as stable as cefoxitin to a wide range of cell-free beta-lactamases. The spectrum and activity of ceftazidime suggest that it may replace the aminoglycosides currently in clinical use.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19802965     DOI: 10.1093/jac/8.suppl_b.5

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Classification of cephalosporins.

Authors:  J D Williams
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Comparative activity in vitro of ceftazidime and nine other antibacterial agents.

Authors:  D S Reeves; H A Holt; M J Bywater
Journal:  Infection       Date:  1983       Impact factor: 3.553

3.  The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.

Authors:  R A Walstad; K Dahl; K B Hellum; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics of ceftazidime in patients with biliary tract disease.

Authors:  R A Walstad; J N Wiig; E Thurmann-Nielsen; T B Halvorsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.